Construction of fusion gene between IgGHV and IL-2 as IgHV nucleic acid vaccine against lymphoma.
- Author:
Hui LIU
1
;
Nai-Bai CHANG
;
Xi-Chun GU
;
Ping ZHU
Author Information
1. Department of Hematology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Cancer Vaccines;
immunology;
Eukaryotic Cells;
metabolism;
Genes, Immunoglobulin;
Genetic Vectors;
Humans;
Immunoglobulin Heavy Chains;
genetics;
Immunoglobulin Variable Region;
genetics;
Interleukin-2;
biosynthesis;
genetics;
Lymphoma;
immunology;
Recombinant Fusion Proteins;
biosynthesis;
genetics;
immunology;
Vaccines, DNA;
biosynthesis;
genetics;
immunology
- From:
Journal of Experimental Hematology
2006;14(6):1160-1162
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to construct the IgHV and IL-2 coexpressed vector. The IgHV gene fragments were obtained from the peripheral blood of patients with lymphoma, and were cloned into eukaryotic expression vector. Meanwhile, the gene fragments of IgHV linked with gene of IL-2 were inserted into pcDNA3.0 to form a fusion gene of IgHV-IL-2. Then fusion genes were transfected into COS cells by Lipofectin and the expression of IL-2 was detected by ELISA. The results showed that the IgHV/pcDNA3.0 expression vector was successfully constructed. The 3' end of IgHV was linked to IL-2 gene, and IL-2 could be correctly expressed. In conclusion, the expression vector of IgHV-IL-2 can express IL-2 correctly in COS cells.
